Our results showed that blocking LIGHT-HVEM/LTβR pathway alleviates I/R-induced kidney injury, which further supports the potential clinical efficacy of LIGHT inhibitors for I/R-AKI in humans. Here, TNFRSF14 is linked to acute kidney injury.